Bristol-Myers Says After Breakfree-2 Study Data Cutoff, One haRMS Patient Experienced A Fatal Event Of Septic Pneumonia

By Reuters News

- Bristol-Myers Squibb Company BMY.N:

  • BRISTOL MYERS SQUIBB PRESENTS RESULTS FROM PHASE 1 BREAKFREE-2 STUDY OF ZOLACABTAGENE AUTOLEUCEL (BMS-986353) IN PATIENTS WITH HIGHLY ACTIVE RELAPSING AND PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AT MSTORONTO 2026

  • BRISTOL-MYERS SQUIBB CO: FOLLOWING DATA CUTOFF, ONE HARMS PATIENT EXPERIENCED A FATAL EVENT OF SEPTIC PNEUMONIA

Further company coverage: BMY.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk